RxDoctor Payments Data

Rosella Jordan, APRN

Family · Grayson, KYNPI 1710577960

Payments from drug & device makers

$1,296in general payments, 2019–2025

Across 81 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$552
  • GSK$264
  • Lilly USA, LLC$82
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • Vanda Pharmaceuticals Inc.$56
  • AstraZeneca$54
  • plus $225 from 9 others

What the payments were for

  • Food & beverage$1,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,296 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,337
Medicare patients
70
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$97,992
JardianceEmpagliflozin49$74,315
FarxigaDapagliflozin Propanediol46$58,614
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$55,680
EliquisApixaban32$49,175
MounjaroTirzepatide40$43,497
JanuviaSitagliptin Phosphate28$43,263
LinzessLinaclotide13$12,785
VascepaIcosapent Ethyl12$10,011
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$7,380
Tresiba Flextouch U-100Insulin Degludec13$6,010
Ventolin HfaAlbuterol Sulfate49$3,130
Albuterol Sulfate HfaAlbuterol Sulfate63$1,891
Levothyroxine Sodium113$1,706
Humulin NInsulin Nph Human Isophane11$1,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$97,99293 claims
AstraZenecaFarxiga$54$58,61446 claims
GSKTrelegy Ellipta$264$55,68049 claims
Lilly USA, LLCMounjaro, Humulin N$82$44,94451 claims
MerckJanuvia$15$43,26328 claims
AbbVieLinzess$552$12,78513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.

Other family in Grayson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →